Change in the total number of shares and votes in Sivers Semiconductors AB
NEW YORK, Nov. 29, 2024 /PRNewswire/ -- The number of shares in Sivers Semiconductors AB (the "Company") as of 29 November 2024 amounts to 237,646,796 shares, of which all shares are ordinary shares. There are currently no issued shares of series C. The total number of shares and votes in the Company as of 29 November 2024 amounts to 237,646,796.
The change in the number of shares and votes in the Company is due to the new issue of 1,762,336 ordinary shares to the CEO that was resolved by the Board of Directors and approved by the Extraordinary General Meeting on 8 November 2024.
For more information, please contact:
Dr. Bami Bastani, Chairman of the Board of Directors
Tel: +1 908 87 28 370
E-mail: bami.bastani@sivers-semiconductors.com
This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980). This information was submitted for publication on 29 November 2024, at 08:00 CET.
About Sivers Semiconductors
We are Critical Enablers of a Greener Data Economy with Energy Efficient Photonics & Wireless Solutions. Our differentiated high precision laser and RF beamformer technologies help our customers in key markets such as AI Data Centers, SATCOM, Defense and Telecom solve essential performance challenges while enabling a much greener footprint. Visit us at: www.sivers-semiconductors.com. (SIV.ST)
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
PR_Sivers_new number of shares_2024-11-29 |
View original content:https://www.prnewswire.com/news-releases/change-in-the-total-number-of-shares-and-votes-in-sivers-semiconductors-ab-302318626.html
SOURCE Sivers Semiconductors
Upcoming Life Sciences Events
- December 2024
- Pre-JPM Partnering Week
- Spectrum of Stem Cell Neuronal Models and Their Purpose Fit
- January 2025
- San Francisco: 8th Annual Neuroscience Innovation Forum
Latest company news
First patient dosed in EXIST Phase 2a study in Parkinson's disease